Hyperion DeFi, Inc. (EYEN)
NASDAQ (CM) NASDAQ (CM) Primary 
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline
On Friday, Eyenovia, Inc. EYEN stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company's Optejet dispensing platform pediatric progressive myopia.
Eyenovia to discontinue late-stage study for eye drug
Eyenovia said on Friday it would terminate a late-stage study testing its experimental drug-device combination for pediatric progressive myopia as it failed to meet the main goal.
Eyenovia, Inc. (EYEN) Q3 2024 Earnings Call Transcript
Eyenovia, Inc. (NASDAQ:EYEN ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - CEO Bren Kern - COO Andy Jones - CFO Conference Call Participants Matthew Caufield - H.C. Wainwright Matt Kaplan - Ladenburg Thalmann Lachlan Hanbury-Brown - William Blair Kemp Dolliver - Brookline Capital Markets Len Yaffe - Stoc Doc Partners Operator Greetings and welcome to Eyenovia's Third Quarter 2024 Earnings Call.
Eyenovia, Inc. (EYEN) Reports Q3 Loss, Misses Revenue Estimates
Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to loss of $0.18 per share a year ago.
Here's Why Eyenovia (EYEN) Is a Great 'Buy the Bottom' Stock Now
Eyenovia (EYEN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Why Is Eye Disease Focused Eyenovia Stock Trading Higher On Thursday?
Eyenovia Inc EYEN stock is trading higher on Thursday after its plunge yesterday, with a session volume of 6.7 million, versus an average volume of 1.33 as per data from Benzinga Pro.
Eyenovia (EYEN) Upgraded to Buy: Here's What You Should Know
Eyenovia (EYEN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Eyenovia, Inc. (EYEN) Q2 2024 Earnings Call Transcript
Eyenovia, Inc. (NASDAQ:EYEN ) Q2 2024 Earnings Conference Call August 12, 2024 4:30 PM ET Company Participants Eric Ribner - IR Michael Rowe - Chief Executive Officer Bren Kern - Chief Operating Officer John Gandolfo - Chief Financial Officer Conference Call Participants Matt Kaplan - Ladenburg Kemp Dolliver - Brookline Capital Markets Lachlan Hanbury-Brown - William Blair Matthew Caufield - H.C. Wainwright Operator Greetings.
Eyenovia, Inc. (EYEN) Reports Q2 Loss, Misses Revenue Estimates
Eyenovia, Inc. (EYEN) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.16 per share a year ago.
Q2 2024 EPS Estimates for Eyenovia, Inc. (NASDAQ:EYEN) Lowered by HC Wainwright
Eyenovia, Inc. (NASDAQ:EYEN – Free Report) – Equities researchers at HC Wainwright decreased their Q2 2024 EPS estimates for shares of Eyenovia in a research report issued to clients and investors on Thursday, May 16th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($0.20) per share for the quarter, down from their prior estimate of ($0.19). HC Wainwright has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Eyenovia’s current full-year earnings is ($0.59) per share. HC Wainwright also issued estimates for Eyenovia’s FY2025 earnings at ($1.00) EPS, FY2027 earnings at ($0.37) EPS and FY2028 earnings at $0.30 EPS. Eyenovia Stock Down 8.6 % Shares of Eyenovia stock opened at $0.75 on Monday. The company has a market cap of $40.40 million, a P/E ratio of -1.00 and a beta of 1.71. The company has a debt-to-equity ratio of 3.72, a quick ratio of 2.16 and a current ratio of 0.88. Eyenovia has a one year low of $0.50 and a one year high of $3.59. The firm has a fifty day moving average of $0.91 and a two-hundred day moving average of $1.41. Eyenovia (NASDAQ:EYEN – Get Free Report) last announced its quarterly earnings data on Monday, March 18th. The company reported ($0.17) EPS for the quarter, hitting analysts’ consensus estimates of ($0.17). During the same quarter in the previous year, the company posted ($0.17) EPS. Hedge Funds Weigh In On Eyenovia A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Leo Wealth LLC acquired a new stake in Eyenovia in the 4th quarter valued at about $34,000. Nations Financial Group Inc. IA ADV acquired a new stake in Eyenovia in the 4th quarter valued at about $84,000. PFG Investments LLC acquired a new stake in Eyenovia in the 1st quarter valued at about $69,000. BNP Paribas Financial Markets grew its stake in Eyenovia by 1,444.4% in the 1st quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock valued at $217,000 after acquiring an additional 205,390 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in Eyenovia by 25.2% in the 1st quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after acquiring an additional 360,924 shares during the last quarter. 25.84% of the stock is owned by institutional investors and hedge funds. Insiders Place Their Bets In other news, major shareholder Stuart M. Grant acquired 100,000 shares of the business’s stock in a transaction on Thursday, March 28th. The stock was bought at an average price of $0.98 per share, for a total transaction of $98,000.00. Following the transaction, the insider now owns 5,430,715 shares in the company, valued at $5,322,100.70. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, major shareholder Stuart M. Grant purchased 50,000 shares of the stock in a transaction dated Tuesday, March 19th. The shares were acquired at an average cost of $1.23 per share, with a total value of $61,500.00. Following the purchase, the insider now directly owns 5,330,715 shares in the company, valued at approximately $6,556,779.45. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Stuart M. Grant purchased 100,000 shares of the stock in a transaction dated Thursday, March 28th. The shares were bought at an average cost of $0.98 per share, for a total transaction of $98,000.00. Following the completion of the purchase, the insider now owns 5,430,715 shares in the company, valued at $5,322,100.70. The disclosure for this purchase can be found here. In the last quarter, insiders bought 160,717 shares of company stock worth $176,433. 7.10% of the stock is owned by insiders. About Eyenovia (Get Free Report) Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. Read More Five stocks we like better than Eyenovia How Technical Indicators Can Help You Find Oversold Stocks MarketBeat Week in Review – 5/13 – 5/17 How to Know if a Stock Pays Dividends and When They Are Paid Out Take-Two Interactive Software Offers 2nd Chance for Investors Investing in Travel Stocks Benefits Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
Brookline Capital Management Equities Analysts Boost Earnings Estimates for Eyenovia, Inc. (NASDAQ:EYEN)
Eyenovia, Inc. (NASDAQ:EYEN – Free Report) – Equities research analysts at Brookline Capital Management boosted their Q2 2024 earnings per share (EPS) estimates for Eyenovia in a research note issued on Thursday, May 16th. Brookline Capital Management analyst K. Dolliver now expects that the company will earn ($0.14) per share for the quarter, up from their previous estimate of ($0.18). The consensus estimate for Eyenovia’s current full-year earnings is ($0.59) per share. Brookline Capital Management also issued estimates for Eyenovia’s Q3 2024 earnings at ($0.14) EPS, Q4 2024 earnings at ($0.14) EPS, FY2024 earnings at ($0.60) EPS, FY2025 earnings at ($0.54) EPS and FY2027 earnings at ($0.06) EPS. Eyenovia (NASDAQ:EYEN – Get Free Report) last posted its earnings results on Monday, March 18th. The company reported ($0.17) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.17). During the same period in the previous year, the company posted ($0.17) EPS. Separately, HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Eyenovia in a research report on Thursday. View Our Latest Report on EYEN Eyenovia Trading Down 8.6 % NASDAQ:EYEN opened at $0.75 on Monday. The company has a market cap of $40.40 million, a P/E ratio of -1.00 and a beta of 1.71. The stock’s fifty day moving average price is $0.91 and its two-hundred day moving average price is $1.41. Eyenovia has a 1 year low of $0.50 and a 1 year high of $3.59. The company has a debt-to-equity ratio of 3.72, a current ratio of 0.88 and a quick ratio of 2.16. Institutional Inflows and Outflows A number of institutional investors have recently added to or reduced their stakes in EYEN. Leo Wealth LLC bought a new position in Eyenovia in the fourth quarter valued at $34,000. PFG Investments LLC bought a new position in Eyenovia in the first quarter valued at $69,000. Nations Financial Group Inc. IA ADV bought a new position in Eyenovia in the fourth quarter valued at $84,000. BNP Paribas Financial Markets grew its stake in shares of Eyenovia by 1,444.4% during the first quarter. BNP Paribas Financial Markets now owns 219,610 shares of the company’s stock valued at $217,000 after buying an additional 205,390 shares during the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Eyenovia by 25.2% during the first quarter. Vanguard Group Inc. now owns 1,790,501 shares of the company’s stock valued at $1,765,000 after buying an additional 360,924 shares during the last quarter. Institutional investors own 25.84% of the company’s stock. Insider Buying and Selling In other Eyenovia news, major shareholder Stuart M. Grant acquired 50,000 shares of the stock in a transaction that occurred on Tuesday, March 19th. The shares were bought at an average price of $1.23 per share, for a total transaction of $61,500.00. Following the completion of the transaction, the insider now owns 5,330,715 shares of the company’s stock, valued at approximately $6,556,779.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other news, major shareholder Stuart M. Grant bought 100,000 shares of Eyenovia stock in a transaction that occurred on Thursday, March 28th. The shares were acquired at an average price of $0.98 per share, with a total value of $98,000.00. Following the completion of the purchase, the insider now directly owns 5,430,715 shares in the company, valued at $5,322,100.70. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Stuart M. Grant bought 50,000 shares of Eyenovia stock in a transaction that occurred on Tuesday, March 19th. The stock was purchased at an average cost of $1.23 per share, for a total transaction of $61,500.00. Following the purchase, the insider now owns 5,330,715 shares of the company’s stock, valued at $6,556,779.45. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 160,717 shares of company stock worth $176,433. Corporate insiders own 7.10% of the company’s stock. About Eyenovia (Get Free Report) Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. Read More Five stocks we like better than Eyenovia Best ESG Stocks: 11 Best Stocks for ESG Investing MarketBeat Week in Review – 5/13 – 5/17 Comparing and Trading High PE Ratio Stocks Take-Two Interactive Software Offers 2nd Chance for Investors What is the S&P 500 and How It is Distinct from Other Indexes Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook
